Dosage forms

Spheryx Awarded Phase II-B NSF SBIR Grant to Support the Development of Total Holographic Characterization®

Retrieved on: 
Tuesday, August 21, 2018
Chemistry, Colloidal chemistry, Nature, Condensed matter physics, Matter, Soft matter, Dosage forms, Materials science, Colloid, Nanoparticle, Holography, Characterization

NEW YORK, Aug. 21, 2018 /PRNewswire/ -- Spheryx, Inc. announced today that the National Science Foundation (NSF) has awarded the company a Phase II-B Small Business Innovation Research (SBIR) grant for $500,000 over 2 years.

Key Points: 
  • NEW YORK, Aug. 21, 2018 /PRNewswire/ -- Spheryx, Inc. announced today that the National Science Foundation (NSF) has awarded the company a Phase II-B Small Business Innovation Research (SBIR) grant for $500,000 over 2 years.
  • This new grant is a continuation of an earlier grant entitled "Total Holographic Characterization of Colloids Through Holographic Video Microscopy" and is for the development of their proprietary Total Holographic Characterization technology.
  • Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization of colloidal materials.
  • Spheryx's proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials' characteristics.

Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine

Retrieved on: 
Monday, August 20, 2018
Chemistry, Pharmacology, Health, Pharmaceutical industry, Thyroid, Dosage forms, RTT, Levothyroxine, Pharmaceuticals policy, Tablet, Norfloxacin, Capsule

"Levothyroxine is one of the most compelling generic product markets in the United States today," said Rob Stewart, President and CEO of Amneal.

Key Points: 
  • "Levothyroxine is one of the most compelling generic product markets in the United States today," said Rob Stewart, President and CEO of Amneal.
  • Moreover, this agreement strengthens our long-term relationship with JSP, which has consistently manufactured Levothyroxine to a high-quality specification for more than 25 years."
  • The agreement includes an upfront milestone payment upon commercialization and a profit share on future sales of Levothyroxine.
  • Jerome Stevens Pharmaceuticals, Inc. is a family owned and operated pharmaceutical manufacturer of prescription tablet and capsule formulations.

Global Wearable Subcutaneous Drug Delivery Markets to 2024 with Profiles of Amgen, Becton Dickinson, Elcam, Insulet, Sensile Medical, SteadyMed, West Pharmaceuticals, Ypsomed & scPharmaceuticals

Retrieved on: 
Wednesday, August 15, 2018
Injection, Medical equipment, Pharmacology, Medicine, Health, Dosage forms, Drug delivery, Subcutaneous injection, Unilife

For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.

Key Points: 
  • For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.
  • What wearable subcutaneous injection devices for drug delivery have been approved for marketing, and what are the key market segments, market dynamics and market demographics?
  • Who are the competitors and participants in the wearable subcutaneous drug delivery segment, and what are their product development activities, business strategies, and business alliances and affiliations?
  • What is the importance of pharma-device alliances and design partnerships on wearable injector drug delivery injector drug delivery market?

Global Wearable Subcutaneous Drug Delivery Markets to 2024 with Profiles of Amgen, Becton Dickinson, Elcam, Insulet, Sensile Medical, SteadyMed, West Pharmaceuticals, Ypsomed & scPharmaceuticals

Retrieved on: 
Wednesday, August 15, 2018
Injection, Medical equipment, Pharmacology, Medicine, Health, Dosage forms, Drug delivery, Subcutaneous injection, Unilife

For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.

Key Points: 
  • For injectable drugs, this pursuit has led to an accelerated evolution in injection device design, creating new opportunities and choices for drug marketers.
  • What wearable subcutaneous injection devices for drug delivery have been approved for marketing, and what are the key market segments, market dynamics and market demographics?
  • Who are the competitors and participants in the wearable subcutaneous drug delivery segment, and what are their product development activities, business strategies, and business alliances and affiliations?
  • What is the importance of pharma-device alliances and design partnerships on wearable injector drug delivery injector drug delivery market?

Global Sustained Release Injectables to 2024: The Trend toward Self-Administration

Retrieved on: 
Tuesday, August 14, 2018
Pharmacology, Pharmacy, Health, Pharmacokinetics, Dosage forms, Routes of administration, Medicinal chemistry, Pharmaceutical formulation, Modified-release dosage, Bolus

Improved drug formulation tech-nology and sophisticated injection deices are converging to create opportunities for sustained release dosing.

Key Points: 
  • Improved drug formulation tech-nology and sophisticated injection deices are converging to create opportunities for sustained release dosing.
  • Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects.
  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Sustained Release Injectables to 2024

Retrieved on: 
Thursday, August 9, 2018
Pharmacology, Health, Pharmacy, Dosage forms, Modified-release dosage, Pharmacokinetics, Market segmentation

What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?

Key Points: 
  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

InventHelp Inventor Develops Personal Care Product Applying Device (HUN-589)

Retrieved on: 
Tuesday, August 7, 2018
Skin care, Dosage forms, Lotion, Toiletry, Sunscreen, Fa, Health, Chemistry, Medicine, Cosmetics

PITTSBURGH, Aug. 7, 2018 /PRNewswire/ -- An inventor from Missouri City, Texas, has developed the BODY LOTION APPLICATOR, a personal care device designed to allow individuals to apply moisturizing lotions, sunscreens, creams and similar products in an easier, more even and less messy fashion.

Key Points: 
  • PITTSBURGH, Aug. 7, 2018 /PRNewswire/ -- An inventor from Missouri City, Texas, has developed the BODY LOTION APPLICATOR, a personal care device designed to allow individuals to apply moisturizing lotions, sunscreens, creams and similar products in an easier, more even and less messy fashion.
  • The BODY LOTION APPLICATOR makes it easier to apply personal care products on hard-to-reach areas of the body.
  • In addition, this device will reduce the mess associated with applying these products.
  • This handy and novel device allows easy and even application of all personal care products.

Pivot Signs Exclusive Co-Marketing And Distribution Agreement with Swiss-based S.T.U. GmbH, Establishes Large Retail and Online Sales Channels In The European Union

Retrieved on: 
Thursday, August 2, 2018
Pharmacology, Dosage forms, Medicine, Health, Skin care, Pivot, Lotion, Topical medication, NPAT

(CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has entered into a Definitive Co-marketing and Distribution Agreement ("the Agreement") with S.T.U.

Key Points: 
  • (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") is pleased to announce that it has entered into a Definitive Co-marketing and Distribution Agreement ("the Agreement") with S.T.U.
  • will market and sell Pivot's proprietary cannabinoid-derived products online and in retail outlets in the U.K., Switzerland, Germany, Austria and Italy (where regulations permit).
  • Pivot Naturals branded products to be distributed and sold in the EU by S.T.U.
  • We look forward to introducing the "Pivot Naturals" brand of topical creams and lotions, oral solutions and capsules to our customers via our growing retail and online sales channels."

United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®

Retrieved on: 
Tuesday, July 31, 2018
Medicine, Health, Dosage forms, Routes of administration, Alcohols, Prostaglandins, Treprostinil, United Therapeutics, Pulmonary hypertension, Infusion pump, Intravenous therapy, Implant

and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin (ISR).

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin (ISR).
  • In December 2017, Medtronic received FDA approval of a premarket application (PMA) for a proprietary intravascular infusion catheter to be used with its SynchroMed II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH).
  • Remodulin was originally approved by the FDA to treat PAH by continuous subcutaneous and intravenous routes of administration in 2002 and 2004, respectively, using external pumps.
  • United Therapeutics funded and Medtronic conducted the DelIVery for PAH clinical trial, which was a safety study of a new implantable catheter designed for intravascular drug (Remodulin) delivery with the SynchroMed II implantable infusion pump.

A Beef Cattle Study: RDDs Deliver Medication Effectively With No Muscle Damage

Retrieved on: 
Monday, July 30, 2018
Injection, Routes of administration, Dosage forms, Subcutaneous injection, Subcutaneous

In Dr. Bechtol' s study, two misconceptions perpetuated by the opponents of RDD were disproved:

Key Points: 
  • In Dr. Bechtol' s study, two misconceptions perpetuated by the opponents of RDD were disproved:
    Can RDDs provide subcutaneous injection?
  • Do RDD injections result in muscle and tissue damage?
  • Among the many findings, Dr. Bechtol concluded that "gross and histopathology results showed an RDD equipped with a " needle having good skin penetration providing subcutaneous injection with no muscle damage."
  • Knowing how remote delivery equipment performs at varying payload capacities relative to distance is crucial to delivering medication successfully.